| Neural activity-related pathways |
|
|
|
|
|
|
|
|
|
|
|
|
| Glutamatergic synapse |
1 |
6 |
1 |
13 |
0 |
1 |
1 |
3 |
1 |
5 |
0 |
1 |
| Morphine addiction |
1 |
5 |
0 |
10 |
0 |
0 |
1 |
3 |
0 |
3 |
0 |
0 |
| Cocaine addiction |
0 |
3 |
1 |
6 |
0 |
1 |
0 |
1 |
1 |
3 |
0 |
1 |
| Cholinergic synapse |
1 |
2 |
0 |
16 |
1 |
2 |
1 |
2 |
0 |
5 |
1 |
2 |
| Axon guidance |
1 |
3 |
0 |
11 |
1 |
1 |
1 |
2 |
0 |
5 |
1 |
1 |
| Long-term depression |
0 |
2 |
0 |
11 |
0 |
0 |
0 |
1 |
0 |
3 |
0 |
0 |
| Serotonergic synapse |
1 |
3 |
0 |
13 |
0 |
0 |
1 |
2 |
0 |
4 |
0 |
0 |
| Neuroactive ligand-receptor interaction |
0 |
5 |
2 |
18 |
0 |
1 |
0 |
2 |
2 |
2 |
0 |
1 |
| GABAergic synapse |
1 |
3 |
0 |
7 |
0 |
0 |
1 |
3 |
0 |
3 |
0 |
0 |
| Circadian entrainment |
1 |
3 |
1 |
12 |
0 |
2 |
1 |
2 |
1 |
4 |
0 |
1 |
| Dopaminergic synapse |
1 |
4 |
0 |
15 |
1 |
3 |
1 |
3 |
0 |
4 |
1 |
2 |
| Nicotine addiction |
0 |
1 |
1 |
1 |
0 |
1 |
0 |
1 |
1 |
1 |
0 |
1 |
| Amphetamine addiction |
0 |
1 |
1 |
6 |
0 |
2 |
0 |
1 |
1 |
2 |
0 |
1 |
| Nicotinate and nicotinamide metabolism |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
| Neurotrophin signaling pathway |
0 |
0 |
0 |
10 |
1 |
2 |
0 |
0 |
0 |
4 |
1 |
2 |
| Digestion-related pathways |
|
|
|
|
|
|
|
|
|
|
|
|
| Bile secretion |
0 |
1 |
0 |
6 |
0 |
0 |
0 |
1 |
0 |
2 |
0 |
0 |
| Insulin secretion |
0 |
2 |
0 |
10 |
0 |
1 |
0 |
1 |
0 |
1 |
0 |
1 |
| Insulin signaling pathway |
0 |
1 |
1 |
9 |
1 |
1 |
0 |
1 |
1 |
5 |
1 |
1 |
| Gastric acid secretion |
0 |
2 |
0 |
12 |
0 |
1 |
0 |
1 |
0 |
2 |
0 |
1 |
| Salivary secretion |
0 |
3 |
0 |
11 |
0 |
0 |
0 |
1 |
0 |
2 |
0 |
0 |
| Pancreatic secretion |
0 |
3 |
0 |
11 |
0 |
0 |
0 |
1 |
0 |
3 |
0 |
0 |
| Immune response-related pathways |
|
|
|
|
|
|
|
|
|
|
|
|
| Lysosome |
1 |
3 |
4 |
14 |
0 |
0 |
1 |
2 |
3 |
4 |
0 |
0 |
| Platelet activation |
0 |
2 |
1 |
14 |
1 |
1 |
0 |
1 |
1 |
3 |
1 |
1 |
| Cytokine-cytokine receptor interaction |
0 |
1 |
0 |
13 |
0 |
0 |
0 |
1 |
0 |
2 |
0 |
0 |
| Toll-like receptor signaling pathway |
0 |
3 |
0 |
12 |
1 |
1 |
0 |
3 |
0 |
5 |
1 |
1 |
| Wnt signaling pathway |
0 |
2 |
0 |
12 |
0 |
1 |
0 |
2 |
0 |
3 |
0 |
1 |
| Inflammatory mediator regulation of TRP channels |
0 |
2 |
0 |
11 |
0 |
1 |
0 |
1 |
0 |
2 |
0 |
1 |
| Chemokine signaling pathway |
1 |
2 |
0 |
10 |
1 |
1 |
1 |
2 |
0 |
4 |
1 |
1 |
| Leukocyte transendothelial migration |
0 |
2 |
2 |
7 |
0 |
1 |
0 |
1 |
2 |
2 |
0 |
1 |
| NF-kappa B signaling pathway |
0 |
1 |
0 |
9 |
0 |
0 |
0 |
1 |
0 |
3 |
0 |
0 |
| Natural killer cell mediated cytotoxicity |
0 |
0 |
1 |
7 |
0 |
1 |
0 |
0 |
1 |
3 |
0 |
1 |
| Fc gamma R-mediated phagocytosis |
0 |
1 |
2 |
5 |
1 |
1 |
0 |
1 |
2 |
3 |
1 |
1 |
| T cell receptor signaling pathway |
0 |
0 |
0 |
7 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| NOD-like receptor signaling pathway |
0 |
1 |
0 |
6 |
0 |
1 |
0 |
1 |
0 |
3 |
0 |
1 |
| Apoptosis |
0 |
1 |
0 |
6 |
1 |
1 |
0 |
1 |
0 |
1 |
1 |
1 |
| Ubiquitin mediated proteolysis |
1 |
0 |
2 |
4 |
1 |
0 |
1 |
0 |
2 |
3 |
1 |
0 |
| Jak-STAT signaling pathway |
0 |
0 |
0 |
6 |
1 |
1 |
0 |
0 |
0 |
1 |
1 |
1 |
| Primary immunodeficiency |
0 |
2 |
0 |
5 |
0 |
0 |
0 |
2 |
0 |
1 |
0 |
0 |
| Antigen processing and presentation |
0 |
1 |
0 |
5 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
| B cell receptor signaling pathway |
0 |
0 |
0 |
4 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Intestinal immune network for IgA production |
0 |
1 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
0 |
| Cancer-related pathways |
|
|
|
|
|
|
|
|
|
|
|
|
| Basal cell carcinoma |
0 |
2 |
0 |
6 |
0 |
0 |
0 |
2 |
0 |
3 |
0 |
0 |
| Transcriptional misregulation in cancer |
0 |
2 |
1 |
11 |
0 |
1 |
0 |
2 |
1 |
2 |
0 |
1 |
| Proteoglycans in cancer |
1 |
2 |
0 |
17 |
2 |
2 |
1 |
2 |
0 |
4 |
2 |
2 |
| Viral carcinogenesis |
0 |
2 |
3 |
13 |
0 |
0 |
0 |
2 |
3 |
3 |
0 |
0 |
| Pathways in cancer |
0 |
3 |
0 |
26 |
1 |
1 |
0 |
3 |
0 |
5 |
1 |
1 |
| Bladder cancer |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
| Acute myeloid leukemia |
0 |
0 |
0 |
6 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Thyroid cancer |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
| Endometrial cancer |
0 |
0 |
0 |
4 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Chronic myeloid leukemia |
0 |
0 |
0 |
5 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Non-small cell lung cancer |
0 |
0 |
0 |
4 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Pancreatic cancer |
0 |
0 |
0 |
4 |
1 |
1 |
0 |
0 |
0 |
4 |
1 |
1 |
| Small cell lung cancer |
0 |
0 |
0 |
3 |
1 |
1 |
0 |
0 |
0 |
2 |
1 |
1 |
| Renal cell carcinoma |
0 |
0 |
0 |
3 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| MicroRNAs in cancer |
1 |
0 |
0 |
6 |
0 |
0 |
1 |
0 |
0 |
3 |
0 |
0 |
| Colorectal cancer |
0 |
0 |
0 |
4 |
1 |
1 |
0 |
0 |
0 |
3 |
1 |
1 |
| Prostate cancer |
0 |
0 |
0 |
9 |
1 |
1 |
0 |
0 |
0 |
4 |
1 |
1 |
